Related Experiment Video
Updated: Jul 11, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Diagnosis and management of primary heart involvement in systemic sclerosis
Giacomo De Luca1,2, Marco Matucci-Cerinic2,3, Sophie I Mavrogeni4,5
1Vita-Salute San Raffaele University.
Insights
Systemic sclerosis primary heart involvement (SSc-pHI) is common but often missed. This review highlights new diagnostic tools like cardiac MRI and therapeutic strategies, including immunosuppressants and antifibrotic drugs, for early SSc-pHI detection and management.
Area of Science:
- Cardiology
- Rheumatology
- Immunology
Background:
- Primary heart involvement (pHI) is a frequent complication of systemic sclerosis (SSc), often presenting asymptomatically.
- Current diagnostic approaches lack specificity, leading to underdiagnosis of SSc-pHI.
- Early identification and management of SSc-pHI are crucial for patient outcomes.
Conclusions:
- Integrating advanced diagnostic tools can improve the early detection of SSc-pHI.
- A structured diagnostic algorithm and therapeutic plan are needed for effective SSc-pHI management.
- Further research into antifibrotic therapies may offer new treatment options for SSc-pHI.
Purpose Of Review:
In systemic sclerosis (SSc) primary heart involvement (pHI) is frequent, even though often unrecognized due to its occult nature and to the lack of a specific diagnostic algorithm. The purpose of this review is to report the state of the art of the evidence in the current literature, as well as the overall diagnostic modalities and therapeutic strategies for primary heart involvement in SSc.
Recent Findings:
SSc-pHI is defined by the presence of cardiac abnormalities that are predominantly attributable to SSc rather than other causes and/or complications; it may be sub-clinical and must be confirmed through diagnostic investigations. Novel electrocardiographic analysis and cardiac magnetic resonance (CMR) with mapping techniques have been recently proposed, showing a great utility in the early identification of SSc-pHI and in the noninvasive characterization of myocardial tissue. Immunosuppressive therapy emerged as fundamental to curb myocardial inflammation, and recent preclinical and clinical data support the role of antifibrotic drugs to treat SSc-pHI.
Summary:
our review will help clinicians to properly integrate the available diagnostic modalities for the assessment of SSc-pHI. The ultimate goal is to propose a feasible diagnostic algorithm for the early identification of patients with SSc-pHI, and a schematic therapeutic approach to manage SSc-pHI.
More Related Videos
08:09Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice
Published on: March 24, 2017
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
Related Concept Videos
Rheumatic Heart Disease III: Medical Management
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease IV: Nursing Management
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care